PMID: 10697305Mar 4, 2000Paper

Candesartan cilexetil in hypertension: effects of six weeks' treatment on haemodynamics, baroreceptor sensitivity and the renin-angiotensin-aldosterone system

Blood Pressure
K FridmanO K Andersson


The effects of the angiotensin II receptor blocker candesartan cilexetil on systemic and forearm haemodynamics and baroreceptor sensitivity were evaluated in this randomized, placebo-controlled, double-blind, crossover study. After a 4-week placebo run-in period, 22 patients with essential hypertension (diastolic blood pressure 100-114 mmHg) were randomized to receive either candesartan cilexetil 16 mg or placebo once daily for 6 weeks. At the end of each period, 24 h after the last dose, invasive haemodynamic assessments were performed. Simultaneously, the plasma renin activity and plasma concentrations of angiotensin II, aldosterone and catecholamines were measured. Compared to placebo, candesartan cilexetil significantly reduced mean arterial pressure by 8 mmHg (95% CI: 2.6; 12.3), while cardiac output, stroke volume and heart rate were unchanged. Forearm vascular resistance was reduced by 1 mmHg x ml(-1) x L x min (CI: 0.3; 2.3). The baroreceptor sensitivity was not influenced, but a change in the set-point was noted. Plasma renin activity and angiotensin II concentrations were increased, while the aldosterone concentration was significantly reduced. Plasma catecholamine concentrations were unaffected. In conclusion, 6 week...Continue Reading


Jan 1, 1978·Acta Medica Scandinavica·O AndersonL Wilhelmsen
Apr 1, 1985·Clinical Science·J J Morton, D J Webb
Dec 1, 1970·Scandinavian Journal of Clinical and Laboratory Investigation·J GieseO Munck
Oct 1, 1971·Circulation Research·B GribbinR Peto
Apr 21, 1982·The American Journal of Cardiology·G ManciaA Zanchetti
Jan 14, 1997·European Journal of Pharmacology·M OjimaK Nishikawa
Feb 7, 1998·Hypertension·G A RongenJ S Floras
Jul 1, 1953·The Journal of Physiology·R J WHITNEY

❮ Previous
Next ❯


Jan 5, 2002·Hypertension Research : Official Journal of the Japanese Society of Hypertension·S Ichikawa, Y Takayama
Jan 30, 2008·Medical & Biological Engineering & Computing·Michael J Mulvany
May 16, 2002·Drugs·Stephanie E Easthope, Blair Jarvis
Dec 14, 2004·Cardiovascular Drug Reviews·Christoph H GleiterKlaus Mörike
Aug 9, 2007·Journal of the Cardiometabolic Syndrome·Kazuo EguchiKazuomi Kario
Oct 10, 2008·The Cochrane Database of Systematic Reviews·Balraj S HeranJames M Wright

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.


Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.